Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) saw a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 2,150,000 shares, a growth of 7.0% from the October 15th total of 2,010,000 shares. Based on an average daily trading volume, of 604,100 shares, the days-to-cover ratio is presently 3.6 days. Currently, 2.7% of the company’s shares are sold short.
Centessa Pharmaceuticals Stock Down 8.6 %
Shares of CNTA traded down $1.50 during trading hours on Friday, hitting $16.00. The company had a trading volume of 730,650 shares, compared to its average volume of 448,872. Centessa Pharmaceuticals has a 52-week low of $5.58 and a 52-week high of $18.74. The firm has a fifty day moving average price of $15.90 and a 200-day moving average price of $12.16. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of -10.46 and a beta of 1.47. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.29 and a current ratio of 21.52.
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.05. On average, equities research analysts forecast that Centessa Pharmaceuticals will post -1.62 EPS for the current fiscal year.
Analysts Set New Price Targets
Check Out Our Latest Analysis on CNTA
Insider Activity at Centessa Pharmaceuticals
In other news, CEO Saurabh Saha sold 4,169 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $12.32, for a total value of $51,362.08. Following the sale, the chief executive officer now directly owns 827,755 shares in the company, valued at approximately $10,197,941.60. This trade represents a 0.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gregory M. Weinhoff sold 16,619 shares of the company’s stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $15.69, for a total value of $260,752.11. Following the transaction, the insider now owns 206,750 shares of the company’s stock, valued at approximately $3,243,907.50. This represents a 7.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 325,031 shares of company stock worth $5,213,043 in the last three months. 11.59% of the stock is owned by insiders.
Institutional Investors Weigh In On Centessa Pharmaceuticals
Institutional investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD boosted its holdings in shares of Centessa Pharmaceuticals by 16.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock valued at $33,427,000 after acquiring an additional 418,615 shares during the last quarter. Nantahala Capital Management LLC purchased a new stake in Centessa Pharmaceuticals in the second quarter worth approximately $4,064,000. Driehaus Capital Management LLC grew its position in Centessa Pharmaceuticals by 89.5% in the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock worth $18,891,000 after purchasing an additional 987,997 shares during the period. First Light Asset Management LLC raised its stake in Centessa Pharmaceuticals by 59.2% during the 2nd quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock valued at $43,168,000 after buying an additional 1,778,515 shares during the last quarter. Finally, GSA Capital Partners LLP boosted its stake in shares of Centessa Pharmaceuticals by 66.1% in the 3rd quarter. GSA Capital Partners LLP now owns 93,658 shares of the company’s stock worth $1,498,000 after buying an additional 37,275 shares during the last quarter. 82.01% of the stock is owned by hedge funds and other institutional investors.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.
Read More
- Five stocks we like better than Centessa Pharmaceuticals
- Canada Bond Market Holiday: How to Invest and Trade
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.